Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep890 | Pituitary and Neuroendocrinology | ECE2023

Case report of a patient with paraganglioma diagnosed after surgery

Cheshlaroska Markushoska Katerina , Milenkovic Tatjana , Cheshlaroska Hristina , Bilaloglu Jovanoska Belma , Tafa Arta

Introduction: Paraganglioma is a tumour derived from extra-adrenal chromaffin cells of the sympathetic paravertebral ganglia of the thorax, abdomen and pelvis. About 36 % to 60 % of the paragangliomas are functional secreting norepinephrine and normetanephrine, which cause hypertension. Non-functional paragangliomas can produce Chromogranin A. Paragangliomas also arise from the parasympathetic ganglia located along the glossopharyngeal and vagal nerves in the neck and at the b...

ea0063p1092 | Pituitary and Neuroendocrinology 3 | ECE2019

Factors predicting dopamine agonist treatment withdrawal in prolactinoma patients

Solak Mirsala , Haxhiu Arta , Haxhiu Arita , Kraljevic Ivana , Dusek Tina , Leskovar Dunja , Polovina Tanja Skoric , Balasko Annemarie , Kastelan Darko

Aim: Dopamine agonist (DA) therapy is recommended as first-line treatment for prolactinomas, albeit with long treatment duration and high recurrence rate after treatment withdrawal. The aim of this retrospective study was to evaluate predictors for successful DA withdrawal.Methods: The study included 59 prolactinoma patients (39 female, 20 male; age 34 (18–82) years) that were treated with DA (35.6% on cabergoline); the duration of treatment was 71 ...